SHIONOGI & CO., LTD.

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare

Osaka, Japan, March 7, 2013 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that ViiV Healthcare (Head Office: London; Chief Executive Officer: Dr. Dominique Limet) has disclosed interim results from SAILING study, which is one of the phase III studies used for the regulatory filings of investigational HIV integrase inhibitor, dolutegravir.

Data from three phase III studies of dolutegravir, from the SPRING-2 and SINGLE studies in treatment-naive patients, and from the VIKING-3 study in HIV-1 infected integrase inhibitor-resistant adults were previously disclosed in April, July and November, 2012. At this time, ViiV Healthcare has disclosed interim results from the SAILING study in treatment-experienced patients. SAILING is the second of two phase III studies in treatment-experienced patients to compare the efficacy and safety of dolutegravir to raltegravir. The data was presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) held in Atlanta, GA, USA this week.

Dolutegravir is an investigational integrase inhibitor for the treatment of patients with HIV infection, which had been developed by Shionogi-ViiV Healthcare LLC, and is currently in development by ViiV Healthcare following the new agreement between Shionogi and ViiV Healthcare announced in October 2012. ViiV Healthcare filed the NDA of dolutegravir in the US, EU and Canada on December 17, 2012, and the United States Food and Drug Administration has already granted a priority review designation.

About the SAILING study

SAILING is a Phase III, multicentre, double blind, double dummy study to compare the efficacy and safety of dolutegravir 50mg once-daily to raltegravir 400mg twice-daily in treatment-experienced, integrase inhibitor-naive adults with HIV-1.

Forward-looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to

build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications
Shionogi & Co., Ltd.
Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099